ClinicalTrials.gg

Program

cebranopadol

Also written as “GRT6005”, “Cebranopadol” and “Cebranopadol 600 µg”.

Its studies are mostly in Pain · Chronic Pain · Acute Pain · Substance-Related Disorders · Osteoarthritis, led by 2 companies.

Furthest: phase 3, since Oct 7, 201318 company-led studies, 2 open or runningNext primary completion: Jan 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tris Pharma160 open or runningphase 3since Oct 7, 2013Mar 24, 2009none ahead
Adneuris Therapeutics22 open or runningphase 3since Sep 22, 2026Sep 22, 2026Jan 2027phase 3 · NCT07845071

Also a collaborator on its studies: AbbVie.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Mar 24, 2009.

  1. Oct 16, 2012Phase 2 study in OsteoarthritisTris Pharma · NCT01709214 · 619 enrolled · United States
  2. Nov 8, 2012Phase 2 study in Low Back PainTris Pharma · NCT01725087 · 1,089 enrolled · Austria, Belgium, Denmark and more
  3. Sep 6, 2013Phase 2 study in Chronic PainTris Pharma · NCT01939366 · 699 enrolled · United States, Austria, Denmark and more
  4. Oct 7, 2013Phase 3 study in PainTris Pharma · NCT01964378 · 200 enrolled · Austria, Belgium, Bulgaria and more
  5. Dec 12, 2013Phase 3 study in PainTris Pharma · NCT02031432 · 76 enrolled · Austria, Belgium, Bulgaria and more
  6. Mar 18, 2019Phase 1 study in PharmacokineticTris Pharma · NCT03882762 · 34 enrolled · United States
  7. May 20, 2019Phase 1 study in Prolonged QTc IntervalTris Pharma · NCT03958123 · 171 enrolled · United States
  8. Feb 16, 2022Phase 1 study in PainTris Pharma · NCT05256108 · 38 enrolled · United States
  9. Jul 27, 2022Phase 1 study in PainTris Pharma · NCT05491785 · 30 enrolled · Netherlands
  10. May 16, 2024Phase 3 study in Acute PainTris Pharma · NCT06423703 · 240 enrolled · United States
  11. Jun 5, 2024Phase 1 study in Substance-Related DisordersTris Pharma · NCT06453265 · 48 enrolled · United States
  12. Aug 6, 2024Phase 3 study in Acute PainTris Pharma · NCT06545097 · 279 enrolled · United States
  13. Sep 22, 2026Adneuris Therapeutics's first study: phase 3 study in PainNew to Adneuris TherapeuticsAdneuris Therapeutics · NCT07845071 · 160 planned · United States
  14. Oct 8, 2026Phase 2 study in Chronic PainAdneuris Therapeutics · NCT07874620 · 45 planned · United States

Ahead

  1. Jan 2027Primary completion: phase 3 study in PainAdneuris Therapeutics · NCT07845071
  2. Mar 2027Primary completion: phase 2 study in Chronic PainAdneuris Therapeutics · NCT07874620

TargetBeta

“An orally available benzenoid that acts as an opioid peptide receptor agonist for the nociceptin/orphanin FQ peptide receptor (opioid receptor like -1; OPRL1; ORL-1; NOP; kappa-type 3 opioid receptor) and the classical opioid receptors, mu, delta and kappa, ”NCIt, by rule
“Nociceptin receptor agonist; Opioid receptors; mu/kappa/delta agonist”ChEMBL 37, by rule

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07874620Chronic Pain · United States2RecruitingAdneuris TherapeuticsMar 202745
NCT07845071Pain · United States3RecruitingAdneuris TherapeuticsJan 2027160
NCT06545097Acute Pain · United States3CompletedTris PharmaDec 30, 2024279
NCT06453265Substance-Related Disorders · United States1CompletedTris PharmaNov 6, 202448
NCT06423703Acute Pain · United States3CompletedTris PharmaJan 31, 2025240
NCT05491785Pain · Netherlands1CompletedTris PharmaMar 30, 202330
NCT05256108Pain · United States1CompletedTris PharmaJul 12, 202238
NCT03958123Prolonged QTc Interval · United States1CompletedTris PharmaNov 27, 2013171
NCT03882762Pharmacokinetic · United States1CompletedTris PharmaSep 17, 201434
NCT02031432Pain · Austria, Belgium, Bulgaria and more3CompletedTris PharmaApr 201676
NCT01964378Pain · Austria, Belgium, Bulgaria and more3TerminatedTris PharmaOct 16, 2015200
NCT01939366Chronic Pain · United States, Austria, Denmark and more2CompletedTris PharmaJan 2015699
NCT01725087Low Back Pain · Austria, Belgium, Denmark and more2CompletedTris PharmaJul 20141,089
NCT01709214Osteoarthritis · United States2CompletedTris PharmaApr 2014619
NCT01357837Osteoarthritis, Knee · Austria, Poland, Spain2CompletedTris PharmaDec 2011207
NCT01347671Pain · Bulgaria, Germany, Romania2CompletedTris PharmaJan 2012189
NCT00878293Diabetic Neuropathies · Germany, United Kingdom2CompletedTris PharmaMay 201090
NCT00872885Pain, Postoperative · United States2CompletedTris PharmaAug 2009258

How it is read

Names in the registry

  • “GRT6005”, 8 entries
  • “Cebranopadol”, 5 entries
  • “Cebranopadol 600 µg”, 3 entries
  • “Cebranopadol 400 ug”, 2 entries
  • “Cebranopadol 1000 µg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.